Liposome-encapsulated aminoglycosides in pre-clinical and clinical studies

Journal of Antimicrobial Chemotherapy

Volumn 48, Issue 3, 2001, Pages 333-344

  Schiffelers, Raymond ^a,b   Storm, Gert ^b   Bakker Woudenberg, Irma ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; GENTAMICIN; KANAMYCIN; LIPOSOME; MACROGOL; OXACILLIN; STREPTOMYCIN; TOBRAMYCIN;

ANIMAL MODEL; BACTERIAL INFECTION; CLINICAL STUDY; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG TARGETING; HUMAN; INFECTION; MONONUCLEAR CELL; MONONUCLEAR PHAGOCYTE; MOUSE; NONHUMAN; RAT; REVIEW; TECHNOLOGY; TOXICITY;

EID: 0034801725     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/48.3.333     Document Type: Review

References (123)

1. The pharmacodynamics of aminoglycosides
2. Aminoglycosides
3. Aminoglycosides-50 years on
4. The utility of aminoglycosides in an era of emerging drug resistance
5. Parenteral aminoglycoside therapy. Selection, administration and monitoring
6. Cell biology of aminoglycoside nephrotoxicity: Newer aspects
7. Effect of streptomycin and gentamicin on the inner ear
8. Laboratory guidelines for monitoring of antimicrobial drugs. National Academy of Clinical Biochemistry
9. The use of aminoglycosides in neutropenic patients
10. Anti-infective strategies in neutropenic patients
11. Management of infections during intensive treatment of hematologic malignancies
12. Clinical strategies for serious infection: A North American perspective
13. Preparation and characterization of liposomes as therapeutic delivery systems: A review
14. The surface properties of phospholipid liposome systems and their characterization
15. Liposomes in drug delivery. Clinical, diagnostic and ophthalmic potential
16. Aminoglycoside nephrotoxicity
17. Modulation of phospholipase A2 activity by aminoglycosides and daptomycin: A Fourier transform infrared spectroscopic study
18. Aminoglycoside antibiotics prevent the formation of non-bilayer structures in negatively-charged membranes. Comparative studies using fusogenic (bis(beta-diethyl-aminoethylether)hexestrol) and aggregating (spermine) agents
19. Molecular basis of the inhibition of gentamicin nephrotoxicity by daptomycin; an infrared spectroscopic investigation
20. Antibacterial activity of liposomal amikacin against Pseudomonas aeruginosa in vitro
21. Incorporation, release and in-vitro antibacterial activity of liposomal aminoglycosides against Pseudomonas aeruginosa
22. Comparison of the bactericidal action of amikacin, netilmicin and tobramycin in free and liposomal formulation against Pseudomonas aeruginosa
23. In-vitro bactericidal efficacy of sub-MIC concentrations of liposome-encapsulated antibiotic against gram-negative and gram-positive bacteria
24. Demonstration of a fusion mechanism between a fluid bactericidal liposomal formulation and bacterial cells
25. The mechanism of enhanced intraphagocytic killing of bacteria by liposomes containing antibiotics
26. Killing of intraphagocytic Staphylococcus aureus by dihydrostreptomycin entrapped within liposomes
27. The use of liposomally-entrapped gentamicin in the treatment of bovine Staphylococcus aureus mastitis
28. Enhanced activity of streptomycin and chloramphenicol against intracellular Escherichia coli in the J774 macrophage cell line mediated by liposome delivery
29. Enhanced intraphagocytic killing of Brucella abortus in bovine mononuclear cells by liposomes-containing gentamicin
30. Treatment of Brucella canis and Brucella abortus in vitro and in vivo by stable plurilamellar vesicle-encapsulated aminoglycosides
31. Effect of composition and method of preparation of liposomes on their stability and interaction with murine monocytes infected with Brucella abortus
32. Intracellular killing of Mycobacterium avium complex by rifapentine and liposome-encapsulated amikacin
33. Differential effects of free and liposome encapsulated amikacin on the survival of Mycobacterium avium complex in mouse peritoneal macrophages
34. Activity of free and liposome encapsulated streptomycin against Mycobacterium avium complex (MAC) inside peritoneal macrophages
35. Efficacies of liposome-encapsulated streptomycin and ciprofloxacin against Mycobacterium avium-M. intracellulare complex infections in human peripheral blood monocyte/macrophages
36. Intracellular delivery and antibacterial activity of gentamicin encapsulated in pH-sensitive liposomes
37. Pharmacokinetics of subconjunctival liposome-encapsulated gentamicin in normal rabbit eyes
38. Intravitreal liposome-encapsulated gentamicin in a rabbit model. Prolonged therapeutic levels
39. Effect of size and lipid composition on the pharmacokinetics of intravitreal liposomes
40. Pharmacokinetics of intravitreally injected liposome-encapsulated tobramycin in normal rabbits
41. Tobramycin liposomes. Single subconjunctival therapy of pseudomonal keratitis
42. Fibrin-enmeshed tobramycin liposomes: Single application topical therapy of pseudomonal keratitis
43. Intravitreal pharmacokinetics of liposome-encapsulated amikacin in a rabbit model
44. Intravitreal liposome-encapsulated drugs: A preliminary human report
45. Enhanced effectiveness of intraperitoneal antibiotics administered via liposomal carrier
46. Topical liposomal delivery of antibiotics in soft tissue infection
47. Liposome delivery of aminoglycosides in burn wounds
48. Liposome encapsulation: A method for enhancing the effectiveness of local antibiotics
49. Soft tissue infection prophylaxis with gentamicin encapsulated in multivesicular liposomes: Results from a prospective, randomized trial
50. Local treatment of prosthetic vascular graft infection with multivesicular liposome-encapsulated amikacin
51. Disposition of liposomal gentamicin following intrabronchial administration in rabbits
52. Pulmonary retention of free and liposome-encapsulated tobramycin after intratracheal administration in uninfected rats and rats infected with Pseudomonas aeruginosa
53. Eradication of mucoid Pseudomonas aeruginosa with fluid liposome-encapsulated tobramycin in an animal model of chronic pulmonary infection
54. In vitro kinetics of drug release and pulmonary retention of micro-encapsulated antibiotic in liposomal formulations in relation to the lipid composition
55. Liposome-cell interactions: In vitro discrimination of uptake mechanism and in vivo targeting strategies to mononuclear phagocytes
56. Fate and behaviour of liposomes in vivo
57. Optimization of liposome behaviour in vivo
58. The interaction of liposomes with the complement system
59. Serum opsonins and liposomes: Their interaction and opsonophagocytosis
60. Fate of injected liposomes: Observations on entrapped solute retention vesicle clearance and tissue distribution in vivo
61. Interactions of liposomes and other drug carriers with the mononuclear phagocyte system
62. Administration of liposomal agents and blood clearance capacity of the mononuclear phagocyte system
63. Doxorubicin entrapped in sterically stabilized liposomes: Effects on bacterial blood clearance capacity of the mononuclear phagocyte system
64. Preparation and properties of liposome-associated gentamicin
65. 3H-dihydrostreptomycin in solution and liposomal form in normal and Mycobacterium tuberculosis infected mice
66. Pharmacokinetics and in vivo activity of liposome-encapsulated gentamicin
67. Treatment of experimental salmonellosis in mice with streptomycin entrapped in liposomes
68. Liposome-encapsulated-amikacin therapy of Mycobacterium avium complex infection in beige mice
69. Treatment of disseminated Mycobacterium avium complex infection of beige mice with liposome-encapsulated aminoglycosides
70. Antibacterial activity of liposome-entrapped streptomycin in mice infected with Mycobacterium tuberculosis
71. Successful treatment using gentamicin liposomes of Salmonella dublin infections in mice
72. Liposome targeting to macrophages: Opportunities for treatment of infectious diseases
73. Concepts on the use of liposomal antimicrobial agents: Applications for aminoglycosides
74. Liposomes in the treatment of infections
75. Enhanced effect of liposome-encapsulated amikacin on Mycobacterium avium-M. intracellulare complex infection in beige mice
76. Liposome-encapsulated-gentamicin therapy of Mycobacterium avium complex infection in beige mice
77. Chemotherapeutic potential of free and liposome encapsulated streptomycin against experimental Mycobacterium avium complex infections in beige mice
78. Treatment of Mycobacterium avium-intracellulare complex infection in beige mice with free and liposome-encapsulated streptomycin: Role of liposome type and duration of treatment
79. TLC G-65 in combination with other agents in the therapy of Mycobacterium avium infection in beige mice
80. Liposome-encapsulated gentamicin treatment of Mycobacterium avium-Mycobacterium intracellulare complex bacteremia in AIDS patients
81. Detection of Mycobacterium avium-intracellulare complex in bone marrow specimens of patients with acquired immunodeficiency syndrome
82. Liposomal amikacin for treatment of M. avium infections in clinically relevant experimental settings
83. Rationale for and efficacy of prolonged-interval treatment using liposome-encapsulated amikacin in experimental Mycobacterium avium infection
84. Therapeutic efficacy of liposome-encapsulated kanamycin against Mycobacterium intracellulare infection induced in mice
85. Free versus liposome-entrapped streptomycin sulfate in treatment of infections caused by Salmonella enteritidis
86. Protective effect of liposomal gentamicin against systemic acute murine brucellosis
87. Treatment of Brucella melitensis infection in mice by use of liposome-encapsulated gentamicin
88. Antibacterial efficacy of gentamicin encapsulated in pH-sensitive liposomes against an in vitro Salmonella enterica serovar typhimurium intracellular infection model
89. The impact of liposome encapsulation of gentamicin on the treatment of extracellular gram-negative bacterial infections
90. Polymer-coated long-circulating micro-particulate pharmaceuticals
91. Sterically stabilized liposomes
92. Surface-modified liposomes: Assessment and characterization for increased stability and prolonged blood circulation
93. Biological properties of sterically stabilized liposomes
94. Long circulating liposome: From concept to clinical reality
95. Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes
96. Localization of sterically stabilized liposomes in Klebsiella pneumoniae-infected rat lung tissue: Influence of liposome characteristics
97. Localization of sterically stabilized liposomes in Klebsiella pneumoniae-infected rat lung tissue: Dependence on circulation kinetics and presence of poly(ethylene) glycol coating
98. Efficacy of gentamicin or ceftazidime entrapped in liposomes with prolonged blood circulation and enhanced localization in Klebsiella pneumoniae-infected lung tissue
99. Altered tissue distribution and elimination of amikacin encapsulated in unilamellar, low-clearance liposomes (MiKasome®)
100. Clinical and preclinical studies with low-clearance liposomal amikacin (MiKasome®)
101. Pharmacokinetics and urinary excretion of amikacin in low-clearance unilamellar liposomes after a single or repeated intravenous administration in the rhesus monkey
102. Liposomes with prolonged blood circulation and selective localization in Klebsiella pneumoniae-infected lung tissue
103. Enhanced localization of liposomes with prolonged blood circulation time in infected lung tissue
104. Scintigraphic evaluation of experimental colitis in rabbits
105. Early detection of liposome brain localization in rat experimental allergic encephalomyelitis
106. Biodistribution and imaging studies of technetium-99m-labeled liposomes in rats with focal infection
107. Sterically stabilized liposomes labeled with indium-111 to image focal infection
108. Contact hypersensitivity: A simple model for the characterization of disease-site targeting by liposomes
109. Imaging experimental intraabdominal abscesses with 99mTc-PEG liposomes and 99mTc-HYNIC IgG
110. Imaging experimental osteomyelitis using radiolabeled liposomes
111. Optimization of technetium-99m-labeled PEG liposomes to image focal infection: Effects of particle size and circulation time
112. Specific accumulation of cholesterol-rich liposomes in the inflammatory tissue of rats with adjuvant arthritis
113. Detecting infection and inflammation with technetium-99m-labeled Stealth liposomes
114. Mechanism of Stealth® liposome accumulation in some pathological tissues
115. The uptake mechanisms of inflammation- and infection-localizing agents
116. Host factors influencing the preferential localization of sterically stabilized liposomes in Klebsiella pneumoniae-infected rat lung tissue
117. Therapeutic efficacy of liposome-encapsulated gentamicin in rat Klebsiella pneumoniae pneumonia in relation to low bacterial susceptibility and impaired host defense
118. UTI treatment using liposomal amikacin (MiKasome®)
119. Comparative efficacies of liposomal amikacin (MiKasome®) plus oxacillin versus conventional amikacin plus oxacillin in experimental endocarditis induced by Staphylococcus aureus: Micro-biological and echocardiographic analyses
120. Efficacy of MiKasome® (a liposomal amikacin formulation) vs free amikacin in experimental endocarditis due to Pseudomonas aeruginosa
121. Prophylactic and therapeutic treatment of gram-negative septicemia with liposomal and non-liposomal encapsulated amikacin in immunocompromised mice
122. Therapy of Mycobacterium avium complex infections in beige mice with streptomycin encapsulated in sterically stabilized liposomes
123. In vivo synergistic activity of liposome-co-encapsulated gentamicin and ceftazidime